All In Biotech

Drug Trial Radar · NCT07553988

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

A Phase II, Open-label, Randomized, Comparative Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

May 14, 2026

Study completion May 9, 2027

Sponsor

Lead sponsor
R-Pharm International, LLCIndustry
Sponsor type
Industry
First posted
Apr 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine the therapeutic dose of RS-113 in patients with metastatic castration-resistant prostate cancer based on efficacy, safety, and pharmacokinetic parameters. The secondary objectives are to assess a pilot efficacy and safety of different doses of RS-113 versus abiraterone, as well as to investigate pharmacokinetics profile and to perform a pilot evaluation of pharmacokinetics parameters of RS-113 in patients with metastatic castration-resistant prostate cancer

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • RS-113, 160 mgDrug

    Hard gelatin capsules, 80 mg

  • RS-113, 240 mgDrug

    Hard gelatin capsules, 80 mg

  • RS-113, 320 mgDrug

    Hard gelatin capsules, 80 mg

  • AbirateroneDrug

    Tablets, 250 mg

  • PrednisoloneDrug

    Tablets, 5 mg

  • Androgen deprivation therapy (ADT)Drug

    * Goserelin: subcutaneous implant, 3.6 mg or 10.8 mg, or * Leuprorelin: lyophilisate for solution for subcutaneous injection, 7.5 mg or 22.5 mg, or * Triptorelin: lyophilisate for solution for intramuscular injection, 3.75 mg, or * Buserelin: lyophilisate for solution for intramuscular injection, 3.75 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Median Progression-free survival (PFS) at 1 year in RS-113 treatment armsTime frame: Up to day 337 (visit 16)

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • State Budgetary Healthcare Institution of the Arkhangelsk Region "Arkhangelsk Oncology Dispensary"

    Arkhangelsk, Russia

  • Moscow City Clinical Oncology Hospital No. 62 of the Moscow Department of Healthcare

    Istra, Russia

  • Ivanovo Regional Oncology Dispensary

    Ivanovo, Russia

  • Kaluga Regional Clinical Oncology Dispensary

    Kaluga, Russia

  • State Budgetary Healthcare Institution "Leningrad Regional Clinical Hospital"

    Kuz'molovskiy, Russia

  • Oncology Center No. 1 of the City Clinical Hospital named after S.S. Yudin of the Moscow Healthcare Department

    Moscow, Russia

  • National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Federal State Autonomous Institution "National Medical Research Center 'Medical and Rehabilitation Center'" of the Ministry of Health of the Russian Federation

    Moscow, Russia

  • Research Lab LLC

    Moscow, Russia

  • Joint-Stock Company "Medsi Group of Companies"

    Moscow, Russia

  • LLC MSCh "Klinitsist-Klinika Pretor"

    Novosibirsk, Russia

  • Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of Saint-Petersburg"

    Saint Petersburg, Russia

  • City Clinical Oncology Dispensary (Saint Petersburg)

    Saint Petersburg, Russia

  • Siberian State Medical University

    Tomsk, Russia

  • Multidisciplinary Clinical Medical Center "Medical City"

    Tyumen, Russia

  • State Institution of Healthcare of Yaroslavl Region "Regional Oncology Hospital"

    Yaroslavl, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.